EMA401A
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $41,760 | 13 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $41,760 | 13 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED DOSE RANGING TRIAL TO DETERMINE THE SAFETY AND EFFICACY OF THREE DOSE LEVELS OF EMA401 IN REDUCING 24 HOUR AVERAGE PAIN INTENSITY SCORE IN PATIENTS WITH POST HERPETIC NEURALGIA EMPHENE | Novartis Pharmaceuticals Corporation | $41,760 | 0 |
Top Doctors Receiving Payments for EMA401A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $41,760 | 13 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $41,760
- Total Doctors 0
- Transactions 13
About EMA401A
EMA401A is a drug associated with $41,760 in payments to 0 healthcare providers, recorded across 13 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2018. In 2018, $41,760 was paid across 13 transactions to 0 doctors.
The most common payment nature for EMA401A is "Unspecified" ($41,760, 100.0% of total).
EMA401A is associated with 1 research study, including "A DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED DOSE RANGING TRIAL TO DETERMINE THE SAFETY AND EFFICACY OF THREE DOSE LEVELS OF EMA401 IN REDUCING 24 HOUR AVERAGE PAIN INTENSITY SCORE IN PATIENTS WITH POST HERPETIC NEURALGIA EMPHENE" ($41,760).